Ionis stock eyes royalties up to 20% on Roche drug win
Ionis stands to earn up to $400M after Roche’s kidney drug clears Phase 3.
Read ArticleIonis stands to earn up to $400M after Roche’s kidney drug clears Phase 3.
Read Article
Ionis stands to earn up to $400M after Roche’s kidney drug clears Phase 3.

CBN rate reset brings the MPR back to life.

Chipper Cash locks in a deal no African fintech has matched

Meta added two checkout partners in a week; Amazon blocked it out

One policy shift could trigger a Medicare insurance shakeout

Airtel Money’s $213 billion fintech empire is heading to London

CBN cuts rate to 23% in a reset the market had already priced in

An unmapped cable corridor keeps draining MTN’s network ambitions

A sweeping draft law may let third parties tap M-PESA data










Markets, deals, policy
Budgeting, retirement, income
Stocks, funds, portfolios
Mortgages, debt, scores
Filing, deductions, accounts
Cash flow, capital, fintech
AI in finance, fintech, automation
Calculators, templates, guides
Newsletter
One email every Sunday. The week’s most useful guides, market-moving stories, and practical tools — chosen by our editors.